French “real life-experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia
详细信息 查看全文
- 作者：Pascale Trioche (1)
Brigitte Nelken (2)
Gérard Michel (3)
Isabelle Pellier (4)
Arnaud Petit (5)
Yves Bertrand (6)
Pierre Rohrlich (7)
Claudine Schmitt (8)
Nicolas Sirvent (9)
Patrick Boutard (10)
Geneviève Margueritte (11)
Brigitte Pautard (12)
Stéphane Ducassou (13)
Dominique Plantaz (14)
Alain Robert (15)
Caroline Thomas (16)
Kristell Desseaux (17)
Sylvie Chevret (17)
André Baruchel (18) - 关键词：Acute lymphoblastic leukaemia ; Childhood leukaemia ; Refractory ; Relapsed ; Leukaemia ; Clofarabine
- 刊名：Experimental Hematology & Oncology
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：1
- 期：1
- 全文大小：292KB
- 参考文献：1. Gaynon PS: Childhood acute lymphoblastic leukaemia and relapse. / Br J Haematol 2005, 131:579-87. CrossRef
2. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. / N Engl J Med 2006, 354:166-78. CrossRef
3. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL: Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a children’s oncology group study. / J Clin Oncol 2008, 26:3971-978. CrossRef
4. Malempati S, Gaynon PS, Sather H, La MK, Stork LC: Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: children’s oncology group study CCG-1952. / J Clin Oncol 2007, 36:5800-807. CrossRef
5. Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS, Loh ML: Factors influencing survival after relapse from acute lymphoblastic leukemia: a children’s oncology group study. / Leukemia 2008, 22:2142-150. CrossRef
6. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML: Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia consortium study. / J Clin Oncol 2010, 28:648-54. CrossRef
7. Kline JP, Larson RA: Clofarabine in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia: a review. / Expert Opin Pharmacother 2005, 6:2711-718. CrossRef
8. Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Weitman S, Secrist JA 3rd: Discovery and development of clofarabine: a nucleoside analogue for treating cancer. / Nat Rev Drug Discov 2006, 5:855-63. CrossRef
9. Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S: Clofarabine: past, present, and future. / Leuk Lymphoma 2007, 48:1922-930. CrossRef
10. Robak T, Korycka A, Lech-Maranda E, Robak P: Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. / Molecules 2009, 14:1183-226. CrossRef
11. Robak T: New nucleoside analogs for patients with hematological malignancies. / Expert Opin Investig Drugs 2011, 20:343-59. CrossRef
12. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O’Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M: Phase 1 clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. / J Clin Oncol 2003, 21:1167-173. CrossRef
13. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O’Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ: Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. / Blood 2003, 102:2379-386. CrossRef
14. Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. / Blood 2004, 103:784-89. CrossRef
15. Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P: Phase 2 study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. / J Clin Oncol 2006, 24:1917-923. CrossRef
16. Kearns P, Michel G, Nelken B, Joel S, Al-Ghazaly E, Beishuizen A, Conter V, Gadner H, Henze G, Smith H, Baruchel A, Saha V: BIOV-111 a European phase 2 trial of clofarabine (Evoltra?) in refractory and relapsed childhood acute lymphoblastic leukemia [abstract]. / Blood 1859, 2006:108.
17. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. / Clin Cancer Res 2001, 7:3580-589.
18. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V: A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. / Blood 2007, 110:1762-769. CrossRef
19. Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL: A multi-center phase 1 study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. / Leukemia 2009, 23:2259-264. CrossRef
20. Locatelli F, Testi AM, Bernardo ME, Rizzari C, Bertaina A, Merli P, Pession A, Giraldi E, Parasole R, Barberi W, Zecca M: Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukemia. / Br J Haematol 2009, 147:371-78. CrossRef
21. Van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, Van Der Schoot CE, Van Dongen JJM: Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. / Leukemia 2007, 21:604-11.
22. O’Connor D, Sibson K, Caswell M, Connor P, Cummins M, Mitchell C, Motwani J, Taj M, Vora A, Wynn R, Kearns PR: Early UK experience in the use of clofarabine in the treatment of relapsed and refractory pediatric acute lymphoblastic leukemia. / Br J Haematol 2011, 154:482-85. CrossRef
23. Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, Kadota R, Cooper T, Shen V, Dahl G, Thottassery JV, Jeha S, Maloney K, Paul JA, Barry E, Caroll WL, Gaynon S: Phase II trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory/relapsed acute lymphoblastic leukemia. / Blood 2011, 118:6043-049. CrossRef
24. Inaba H, Bhojwani D, Pauley JL, Pei D, Cheng C, Metzger ML, Howard SC, Rubnitz JE, Sandlund JT, Ribeiro RC, Leung W, Campana D, Pui CH, Jeha S: Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. / Br J Haematol 2012, 156:275-79. CrossRef - 作者单位：Pascale Trioche (1)
Brigitte Nelken (2)
Gérard Michel (3)
Isabelle Pellier (4)
Arnaud Petit (5)
Yves Bertrand (6)
Pierre Rohrlich (7)
Claudine Schmitt (8)
Nicolas Sirvent (9)
Patrick Boutard (10)
Geneviève Margueritte (11)
Brigitte Pautard (12)
Stéphane Ducassou (13)
Dominique Plantaz (14)
Alain Robert (15)
Caroline Thomas (16)
Kristell Desseaux (17)
Sylvie Chevret (17)
André Baruchel (18)
1. Department of Pediatric, APHP, H?pital Antoine Béclère, Service de Pédiatrie, 157 rue de la porte de Trivaux, 92141, Clamart Cedex, France
2. CHU, Lille, France
3. H?pital La Timone, APHM, Marseille, France
4. CHU, Angers, France
5. APHP, H?pital Armand Trousseau, Paris, France
6. CHU, Lyon, France
7. CHU, Besan?on, France
8. CHU, Nancy, France
9. CHU, Nice, France
10. CHU, Caen, France
11. CHU, Montpellier, France
12. CHU, Amiens, France
13. CHU, Bordeaux, France
14. CHU, Grenoble, France
15. CHU, Toulouse, France
16. CHU, Nantes, France
17. APHP, H?pital Saint-Louis, Département de Biostatistique et Informatique Médicale, Paris et Université Paris Diderot, Paris, France
18. APHP, H?pital Robert Debré, Hématologie et Immunologie Pédiatrique, Paris, et Université Paris Diderot, Paris, France - ISSN：2162-3619
文摘
Background Clofarabine alone or in combination with cyclophosphamide and etoposide has shown a good efficacy and a tolerable toxicity profile in previous studies of children with relapsed or refractory leukaemia. This report describes a retrospective study of 38 French patients who received clofarabine as a monotherapy or in combination for relapsed or refractory acute lymphoblastic leukaemia (ALL) outside of clinical trials after marketing authorization. Methods We retrospectively analysed data for 38 patients, up to 21 years old, attending 17 French centres. Thirty patients received clofarabine alone or in combination for a bone marrow relapse of acute lymphoblastic leukaemia (ALL) or refractory disease and eight patients for a high level of minimal residual disease (MRD). Survival and response durations were estimated by the Kaplan-Meier method. Results For the 30 patients who received clofarabine for a bone marrow relapse of ALL (number of relapse, 1-3; median, 1), the overall remission rate (ORR) was 37%: eight complete remission (CR) and three complete remission without platelet recovery (CRp). Ten of the 11 responding patients subsequently underwent haematopoietic stem cell transplantation (HSCT). Only four of the eight patients who received clofarabine while in remission for a high level of MRD, showed a moderate improvement of MRD. Seven of these eight patients received HSCT and six of them were alive at the end of the study. One other patient was alive without receiving HSCT. However, clofarabine treatment was associated with a high risk of infection and hepatotoxicity. Febrile neutropenia grade ?3 was reported in 79% of patients and documented infections grade ?3 occurred in nine patients (24%). Hepatotoxicity grade 3 was reported in nine patients (24%). We observed four deaths related to treatment. Conclusion In our experience, the efficacy of clofarabine is poorer than previously reported. Its toxicity is high and can be life threatening. Prospective studies on clofarabine used during earlier phases of the disease may help to define how best this new drug can be exploited for childhood and adolescent ALL.